Recent attention on COMPASS Pathways (CMPS) centers on its first quarter 2026 earnings and a series of key regulatory steps for COMP360 in treatment resistant depression, including a rolling FDA New ...

Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely ...

Compass Pathways stock jumped Wednesday after the psychedelics-tied biotech significantly boosted its cash holdings.

Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based ...

These 3 Psychedelic Stocks Activated After Trump's Executive Order Compass Pathways (NASDAQ:CMPS) said it has begun a rolling ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...

FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating momentum 26-week (Part B) data from COMP006, ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards ...